Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study

Trial Profile

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms STAT Study
  • Most Recent Events

    • 22 Feb 2023 Results presented in the Mannkind pharma media release.
    • 22 Feb 2023 According to Mannkind media release, the oral presentation describing meal challenge results will be presented at the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Berlin from February 22nd-25th.
    • 03 Jun 2021 According to a MannKind Corporation media release, a post hoc analysis of this trial will be presented at the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2021) to be held virtually.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top